samaritan_12b25-093008.htm
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check
One): [ ] Form
10-K [ ] Form
11-K [ ] Form
20-F [x] Form
10-Q [ ] Form
10-N-SAR
For
Quarter Ended: September 30, 2008
[
] Transition Report on Form 10-K [ ]
Transition Report on Form 10-Q
[
] Transition Report on Form 20-F [
] Transition Report on Form N-SAR
[
] Transition Report on Form 11-K
For the
Transition Period Ended: ________________________________
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART
I
REGISTRANT
INFORMATION
Samaritan
Pharmaceuticals, Inc.
Full Name
of Registrant:
101
Convention Center Drive, Suite 310
Address
of Principal Executive Office (Street and Number):
Las
Vegas, Nevada 89109
City,
State and Zip Code:
PART
II
RULE
12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check appropriate box)
[x] (a) The
reasons described in reasonable detail in Part III of this form could not be
eliminated without unreasonable effort or expense;
[x] (b) The
subject annual report, semi-annual report, transition report on Form 10-K, 20-F,
11-K or Form N-SAR, or portion thereof will be filed on or before the 15th
calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q, or portion thereof will be filed on or before
the fifth calendar day following the prescribed due date; and
[x] (c) The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been
attached if applicable.
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or
the transition report portion thereof could not be filed within the prescribed
time period. (Attach extra sheets if needed.)
The
Company was unable to file with in the prescribed time period because of pending
additional information necessary for finalizing its Form 10-Q.
PART
IV
OTHER
INFORMATION
(1) Name
and telephone number of person to contact in regard to this
notification
Eugene
J.
Boyle (702) 735-7001
(Name) (Area
Code) (Telephone
Number)
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during
the preceding 12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If the answer is no, identify
report(s). [x] Yes [ ] No
(3) Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof? [x]
Yes [ ] No
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
SAMARITAN
PHARMACEUTICALS, INC.
(Name of
Registrant as specified in Charter)
Has duly
caused this notification to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Date:
November 14, 2008
|
By:
/s/ Eugene J. Boyle
|
| |
Eugene
J. Boyle
Chief
Financial Officer
|